Clinical Trials
Find Reliable Skins Treatment at Dermatology Specialists of Charlotte
Tremfya
Phase lllb clinical trial, being conducted by Janssen Research and Development, evaluating Guselkumab (Tremfya) for the treatment of moderate-severe plaque or scalp psoriasis in skin of color.
This trial consists of a 48-weeks blinded treatment period and a 100-week long term extension. During the primary 16-weeks of the trial, there will be a placebo cohort. After this, all participants will receive guselkumab 100mg Q8wks for the remainder of the treatment period and long-term extension.
Previous trials for Tremfya included 77-93% white participants. The trial will specifically enroll patients who self-identify as a person of color. The main study requirements are listed below.
If a subject qualifies for the trial, all medical care related to the trial and the study medication, Tremfya, will be supplied as no cost. Subject will also be paid a stipend for their time and travel expenses.
If you have any patients that may be interested or have questions regarding the trial, please reach out to Abbey Harwell at 704-943-3714 ext. 117 or abbey.harwell@djlresearch.com.
Have questions or concerns? Please give us a call at 704-943-3714.